Inner page banner-Company news


Introduction and main indications of erythropoietin (EPO)

Erythropoietin (Erythropoietin, EPO) is also a colony stimulating factor, which can promote the expansion and differentiation of bone marrow erythroid colony forming units, and cooperate with other cell growth factors to promote cell proliferation and differentiation, inhibit cell apoptosis, and increase the number of red blood cells. . After the EPO cDNA was successfully cloned in 1985, rhEPO has gradually been widely used in the treatment of various anemia diseases. At present, the indications of rhEPO drugs in China are mainly for the treatment of anemia caused by chronic kidney disease (CKD) and the treatment of anemia caused by chemotherapy. (cancer related anemia, CRA). It has become one of the important support methods for the treatment of anemia.

Renal Anemia

It refers to anemia caused by the relative or absolute deficiency of erythropoietin (EPO) caused by various kidney diseases, and anemia caused by some toxic substances in the plasma of uremia patients by interfering with the production and metabolism of red blood cells.

Renal anemia in China presents the status quo of "one high and two low" diseases, that is, high prevalence, low treatment rate, and low compliance rate.

High prevalence: The prevalence of anemia in CKD1-5 patients is 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%. The prevalence of anemia in dialysis and non-dialysis CKD patients was 98.2% and 52.0%, respectively.

Low treatment rate: The awareness rate of anemia in chronic kidney disease 1-5 non-dialysis patients is low, and the treatment rate of anemia patients is only 1/3. National data show that almost half of new dialysis patients have not received anemia correction before dialysis, and anemia is more serious in rural dialysis patients in the central and western regions.

Low treatment compliance rate: Patients with renal anemia after dialysis also have insufficient treatment and low compliance rate. The national hemodialysis registration data report shows that the average hemoglobin compliance rate of hemodialysis patients in 2011 was only 21.3%.